Background. Historically, multiple ipsilateral breast cancer (MIBC) has been a contraindication to breastconserving therapy (BCT). We report the feasibility of BCT in MIBC from the ACOSOG Z11102 trial [Alliance], a single arm noninferiority trial of BCT for women with two or three sites of malignancy in the ipsilateral breast. Methods. Women who enrolled preoperatively in ACO-SOG Z11102 were evaluated for conversion to mastectomy and need for reoperation to obtain negative margins. Characteristics of women who successfully underwent BCT and those who converted to mastectomy were compared. Factors were examined for association with the need for margin reexcision. Results. Of 198 patients enrolled preoperatively, 190 (96%) had 2 foci of disease. Median size of the largest tumor focus was 1.5 (range 0.1-7.0) cm; 49 patients (24.8%) had positive nodes. There were 14 women who underwent mastectomy due to positive margins, resulting in a conversion to mastectomy rate of 7.1% (95% confidence interval [CI] 3.9-10.6%). Of 184 patients who successfully completed BCT, 134 completed this in a single operation. Multivariable logistic regression analysis did not identify any factors significantly associated with conversion to mastectomy or need for margin reexcision. Conclusions. Breast conservation is feasible in MIBC with 67.6% of patients achieving a margin-negative excision in a single operation and 7.1% of patients requiring conversion to mastectomy due to positive margins. No characteristic was identified that significantly altered the risk of conversion to mastectomy or need for reexcision. ClinicalTrials.gov Identifier. NCT01556243.
More recently, mammographic quality has improved and utilization of new imaging techniques, including breast MRI, has increased. More sensitive imaging modalities have increased the detection of previously radiographically occult disease. Local control rates in patients undergoing breast-conserving therapy are improving, particularly in those patients with hormone receptor-positive disease. At the same time, the finding of MIBC is increasing and is now reported at rates ranging from 13-75%. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] With this higher detection rate, patients and clinicians are increasingly faced with the question of how best to manage MIBC surgically.
Retrospective series reporting outcomes for women treated more recently, in the 2000s and 2010s, have found rates of LRR comparable to those reported for unifocal disease in appropriately selected patients with MIBC. [18] [19] [20] [21] [22] The American College of Surgeons Oncology Group (ACOSOG) Z11102 prospectively evaluated the feasibility and safety of breast conservation in women with MIBC. The primary endpoint of Z11102 is LRR at 5 years. Secondary endpoints include rate of conversion to mastectomy. Multifocal breast cancer has been traditionally defined as two or more foci of disease in a single quadrant of the breast. Multicentric disease has been defined as two or more foci in more than one quadrant of the breast. This distinction is relatively arbitrary as multicentric lesions may have minimal separation (particularly when closer to the nipple) while multifocal tumors may be separated by significant distance within the same quadrant of a large breast. Therefore, Z11102 used the term multiple ipsilateral breast cancer and included patients with tumors separated by 2 cm or greater of normal breast tissue. 16 We report the feasibility of breast conservation for MIBC and assess factors associated with reexcision and conversion to mastectomy in the Z11102 trial.
METHODS
ACOSOG Z11102 is a prospective, single-arm, noninferiority trial designed to assess the feasibility of breast conservation in women with two or three sites of malignancy in a single breast. ACOSOG is now part of the Alliance for Clinical Trials in Oncology. All sites received approval from their institutional review boards, and written, informed consent was obtained from patients prior to study enrollment. Inclusion criteria required biopsy of all suspicious lesions prior to surgery and a minimum of one site of invasive carcinoma. The remaining lesions could be ductal carcinoma in situ (DCIS) or invasive carcinoma. Additional eligibility criteria included female gender, life expectancy [5 years, age older than 40 years, and cN0 or N1 disease. Initially, magnetic resonance imaging (MRI) within 60 days before surgery was required in addition to mammogram. The MRI requirement was removed in an amendment activated May 2015. Exclusion criteria included: pregnancy, neoadjuvant endocrine or chemotherapy, a single radiographic site of disease larger than 5 cm, bilateral breast cancer (synchronous or metachronous), comorbidity precluding whole breast radiation, history of prior ipsilateral breast irradiation, plan for partial breast irradiation, or a known BRCA mutation. Patients were initially all registered for the study preoperatively. An amendment effective May 2015 allowed postoperative registration if this occurred before initiation of radiation therapy. These patients were not included in this analysis. For women registered before surgery, enrollment was based on radiographic distance between lesions. The protocol required a minimum of 3 cm of normal-appearing breast tissue between lesions before an amendment (effective January 2014) that decreased the minimum distance between lesions to 2 cm.
Excision through a single or multiple incisions was allowed. At the outset of the trial, negative margins were defined as a minimum of 2 mm, excepting anterior and posterior margins if skin and/or fascia were taken. Reexcision was recommended for patients with margins \2 mm. After the publication of the Society of Surgical Oncology/American Society of Radiation Oncology consensus guidelines on margins, the was protocol was amended, effective May 2015, defining negative margin for invasive breast cancer as ''no ink on tumor.'' For patients with persistently positive margins after attempted BCT, mastectomy was recommended. Oncoplastic reconstruction was allowed. Adjuvant systemic therapy was prescribed at the discretion of the treating oncologist. Hormone receptor positivity was defined per individual institutional policies.
Radiation target delineation was performed according to the RTOG contouring consensus definitions. Radiation was delivered with standard fractionation of 1.8 to 2.0 Gy daily for a total whole breast dose of 45-50 Gy. A radiation boost of 10-16 Gy in 2.0-Gy daily fractions to each tumor bed was mandatory. The protocol required that no more than 40% of the target breast tissue receive over 60 Gy. Hypofractionation was not allowed. Women who could not undergo radiation boost were excluded from the trial. All radiation plans were submitted for central review.
Data collection and statistical analyses were conducted by the Alliance Statistics and Data Center. Data quality was ensured by review of data by the Alliance Statistics and Data Center and by the study chairperson following Alliance policies. The Alliance Data Safety Monitoring Board reviewed safety data for this trial at least twice per year.
Statistical Analysis
The data for this analysis were last updated on February 28, 2018. Comparison of categorical variables between women who completed BCT and those who converted to mastectomy was performed with a Chi square test or a Fisher's exact test, when appropriate. Continuous variables were compared using a two-sample t-test or Wilcoxon rank-sum test, as appropriate. The association of variables with a dichotomous outcome (conversion to mastectomy or need for reexcision) was evaluated with a logistic regression model. Multivariable logistic regression was to be performed using all variables found to be significant in the univariate analysis. The a priori level of significance was 0.05, and all p values are two-sided. The analyses were performed by using SAS (9.4.).
RESULTS
Two hundred twenty-three eligible patients were enrolled between July 23, 2012 and August 19, 2016. Of this group, 198 enrolled preoperatively and are the subjects of this report. Patient characteristics can be found in Table 1 . The median age was 62 (range 40-87) years. The majority of patients (190, 96.0%) had 2 foci of disease identified on preoperative biopsy, while 8 patients (4.0%) had 3. In the 190 women with 2 sites of disease, in 112 patients (59.0%), all sites of disease were invasive ductal carcinoma (IDC). There were 42 patients (22.1%) with one site of ductal carcinoma in situ (DCIS) and one site of IDC, 16 patients (8.4%) had invasive lobular carcinoma (ILC) at all sites, 18 patients (9.5%) had one site of IDC site and one of ILC, and 2 patients (1.0%) had one site of DCIS site and one ILC. In the 8 women with 3 sites of disease, 4 had IDC at all sites, 2 had IDC and DCIS, 1 had a combination of IDC and ILC, and 1 had ILC and DCIS. The majority of patients had at least one tumor that was estrogen receptor (ER)-positive (95.5%) and 91.4% had progesterone receptor (PR)-positive tumors. Twenty women (10.1%) had at least one site of HER2? disease. Forty-nine patients (24.8%) had node-positive disease. Median size of the largest lesions on preoperative imaging was 1.7 (range 0.8-5.0) cm. Median pathologic size of the largest single focus of tumor (invasive or DCIS) was 1.5 (range 0.12-7.0) cm. On final pathology, 8 patients (4.0%) had one single contiguous lesion. Six of these 8 patients had successful BCT and 2 (25%) converted to mastectomy. In contrast, 12 of 190 (6.3%) women who did not have a single contiguous lesion converted to mastectomy (p = 0.10).
Of the 198 patients, 184 (92.9%, 95% CI 89.4-96.5) successfully completed BCT, while 14 patients (7.1%, 95% CI 3.5 to 10.6) ultimately underwent mastectomy due to persistently positive margins (Fig. 1) . Of the patients who successfully completed BCT, the majority (134, 73.6%; 95% CI 67.2-80.0) successfully completed breast conservation in a single operation, 42 patients (23.1%) had a second operation to achieve negative margins, 5 (2.7%) required 3 operations, and a single patient (0.5%) underwent 5 procedures to obtain negative margins. Two patients in the BCT group did not achieve negative margins; of these, one declined additional surgery and one had a focally positive deep margin after excision of fascia and no additional surgery was recommended. In the conversion to mastectomy group, 13 (93%) women underwent 2 operations and 1 underwent 4 operations (Fig. 2) . After the margin amendment, the total number of patients completing BCT in a single operation trended up from 64.1% to 74.6% (p = 0.12) (Fig. 3) .
For the 184 patients who completed BCT, 154 (84.2%) had routine closure by breast surgeon, 23 (12.6%) had local tissue rearrangement by a breast surgeon, 3 (1.6%) had breast reshaping by a plastic surgeon, and 3 (1.6%) had simultaneous breast reduction by a plastic surgeon. Data were missing for one patient. In the mastectomy group, one woman opted for contralateral prophylactic mastectomy. Sixteen patients in the BCT group had contralateral surgery (4 had excisional biopsy, 4 had mastopexy, 6 had breast reduction, 2 had a contralateral procedure that was not specified).
Factors potentially associated with conversion to mastectomy were assessed, including patient age, use of preoperative MRI, number of foci of disease identified preoperatively, median pathologic tumor size, number of lumpectomies, nodal status, tumor grade, hormone receptor and HER2 status, and histology, including DCIS or ILC at one or more sites of disease. None of these factors were associated with conversion to mastectomy on univariate analysis. The median largest radiographic tumor size was 1.7 cm in the BCT group and 1.6 cm in the group that converted to mastectomy (p = 0.97). In the BCT group, median pathologic size was 1.4 cm compared with 2.1 cm in the group that converted to mastectomy (p = 0.17). In the BCT group, 75% of the patients had low-or intermediategrade tumors, while in the conversion to mastectomy group 93% of the patients had low-or intermediate-grade tumors (p = 0.17). Node-positive disease was found in 50% (7/14) of the women converted to mastectomy compared with 23% (42/184) in the BCT group (p = 0.17).
Of the 116 patients with IDC at all sites, the conversion rate to mastectomy was 8 of 116 (6.9%), whereas in cases with ILC at both sites the conversion rate was 12.5% (2/ 16), and in cases with one site of IDC and one site of ILC it was 10.5%. In aggregate, patients with ILC at any site had a 10.5% (4/38; 95% CI 0.9-22.0) rate of conversion to mastectomy. In the 47 patients with DCIS at one site and invasive disease at the other site(s), the conversion rate to 9%) ; p = 0.73) were significantly associated with conversion to mastectomy. HER2 status also was not found to be significantly associated with conversion to mastectomy in women with MIBC (p = 0.37). In the successful BCT cohort, 11.2% (20/ 178) had at least one HER2-positive lesion. None of the 14 patients with mastectomy had HER2-positive disease ( Table 1) .
The same factors were assessed for association with reoperation for margin reexcision. None of the variables analyzed were found to be associated with number of operative procedures (Table 2) .
DISCUSSION
Breast-conserving surgery is technically feasible in women with MIBC, with a low rate of conversion to mastectomy (7.1%); most women successfully achieve breast conservation with negative margins in a single operation (67.6%). Long-term LRR data are necessary to assess oncologic outcomes. These will be reported from the ACOSOG Z11102 trial when the data are sufficiently mature.
Several retrospective studies have reported acceptable LRR rates following BCT in the MIBC population. One of the largest was a review of 476 patients treated with BCT for MIBC between 1997 and 2002 with a 5.1% LRR 20 This cohort had more advanced disease with 55% of all patients being node positive compared with 25% in the Z11102 trial. Ataseven et al. reviewed the surgical management of women with MIBC treated with neoadjuvant chemotherapy. 22 Patients with operable or locally advanced breast cancer who were enrolled on several neoadjuvant cooperative group trials were evaluated for local recurrence-free survival (LRFS), disease-free survival (DFS), and overall survival (OS). Of the 6134 patients accrued, 22.9% were found to have MIBC. Patients who achieved margin negative resection or a pathologic complete response had no statistically significant difference in LRFS when comparing unifocal to MIBC. Of note, the Z11102 trial excluded patients treated with neoadjuvant therapy.
The data from Z11102 establish the feasibility of performing BCT for MIBC with a rate of conversion to mastectomy being acceptably low (7.1%). This is consistent with studies that report the rate of conversion to mastectomy in women with unifocal breast cancer ranging between 4% (after SSO/ASTRO consensus guidelines regarding surgical margins) and 11%. 23, 24 Risk factors for conversion to mastectomy cited in other studies include nodal positivity, invasive lobular carcinoma, and DCIS. Additionally, studies have documented HER2 status and tumor size as risk factors for margin reexcision. [25] [26] [27] In our study, none of these previously identified risk factors influenced the need for conversion to mastectomy. This is likely due to the small size of the conversion to mastectomy cohort, which is a significant limitation of the study, because the study was not powered for rates of conversion to mastectomy.
The reexcision rate in Z11102 of 32.4% is slightly higher than expected compared with patients with unifocal disease. 23, [28] [29] [30] This rate decreased after the guideline amendment supporting no ink on tumor. Additionally, only 3.6% of patients required more than two operations in this study. Although multiple surgical procedures have been shown to be oncologically safe, they are costly, stressful to patients, potentially compromise cosmetic outcome, and may delay systemic or local therapy. 18 No variables were identified that predicted the need for a subsequent procedure for MIBC.
CONCLUSIONS
The Z11102 trial demonstrates acceptably low (7.1%) risk of conversion to mastectomy in women with MIBC. The majority of these women (67.6%) require one operation to successfully complete BCT with negative margins. These data may inform conversations between patients and surgeons regarding management of MIBC. Based on these data, no specific patient, imaging, or tumor factor accurately predicts patients at highest risk for failure of BCT in the MIBC population. Additional data are awaited from this trial regarding LRR following BCT for women with MIBC. ALND axillary lymph node dissection, DCIS ductal carcinoma in situ, ER estrogen receptor, G grade, HER2 human epidermal growth factor receptor, N node, PR progesterone receptor, SLND sentinel lymph node dissection
